GT200900295A - Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias. - Google Patents
Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias.Info
- Publication number
- GT200900295A GT200900295A GT200900295A GT200900295A GT200900295A GT 200900295 A GT200900295 A GT 200900295A GT 200900295 A GT200900295 A GT 200900295A GT 200900295 A GT200900295 A GT 200900295A GT 200900295 A GT200900295 A GT 200900295A
- Authority
- GT
- Guatemala
- Prior art keywords
- treatment
- agent
- pharmaceutical composition
- combination
- ciprofloxacine
- Prior art date
Links
- 239000004599 antimicrobial Substances 0.000 title abstract 2
- 239000003963 antioxidant agent Substances 0.000 title abstract 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title 2
- 229960005070 ascorbic acid Drugs 0.000 title 1
- 235000010323 ascorbic acid Nutrition 0.000 title 1
- 239000011668 ascorbic acid Substances 0.000 title 1
- 229960003405 ciprofloxacin Drugs 0.000 title 1
- 208000019206 urinary tract infection Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 2
- -1 ASCÓRBICO ACID Chemical compound 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA COMPUESTA POR LA COMBINACIÓN SINÉRGICA DE UN AGENTE ANTIMICROBIANO, CONOCIDO COMO: CIPROFLOXACINO Y UN AGENTE ANTIOXIDANTE, TAL COMO: ÁCIDO ASCÓRBICO (VITAMINA C), ADEMÁS DE EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES, MISMOS QUE SE ENCUENTRAN FORMULADOS EN UNA SOLA UNIDAD DE DOSIS PARA SER ADMINISTRADA POR VÍA ORAL, UTILIZADA PARA EL TRATAMIENTO DE INFECCIONES URINARIAS, LA CUAL PROPORCIONA UN MAYOR EFECTO TERAPÉUTICO, UN INCREMENTO EN EL APEGO POR EL TRATAMIENTO Y LA REDUCCIÓN DE LA INFECCIÓN EN MENOR TIEMPO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2007006334A MX2007006334A (es) | 2007-05-28 | 2007-05-28 | Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200900295A true GT200900295A (es) | 2011-11-15 |
Family
ID=40075300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200900295A GT200900295A (es) | 2007-05-28 | 2009-11-12 | Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2149374B1 (es) |
| AR (1) | AR067320A1 (es) |
| BR (1) | BRPI0811627A2 (es) |
| CL (1) | CL2008001536A1 (es) |
| CO (1) | CO6241114A2 (es) |
| CY (1) | CY1113544T1 (es) |
| EC (1) | ECSP099733A (es) |
| ES (1) | ES2394736T3 (es) |
| GT (1) | GT200900295A (es) |
| MX (1) | MX2007006334A (es) |
| PE (1) | PE20090316A1 (es) |
| PL (1) | PL2149374T3 (es) |
| WO (1) | WO2008147167A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017111718A1 (en) * | 2015-12-25 | 2017-06-29 | Yusuf Toktamiş Öğün | The formulation comprising phosphomycine and ascorbic acid for the treatment of bacterial urinary system infections |
| RU2637650C2 (ru) * | 2016-03-29 | 2017-12-05 | Общество с ограниченной ответственностью "ОКТАВА ХОЛДИНГ" | Композиция для профилактики заболеваний мочевыводящих путей |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020169112A1 (en) * | 2001-05-08 | 2002-11-14 | Luc Montagnier | Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections |
| US20050085446A1 (en) * | 2003-04-14 | 2005-04-21 | Babu M.K. M. | Fluoroquinolone formulations and methods of making and using the same |
| US8003616B2 (en) * | 2004-04-23 | 2011-08-23 | Albert Rory J | Composition for the treatment of ear infections and method |
| US8153166B2 (en) * | 2006-06-08 | 2012-04-10 | Chih-Hsiung Lin | Composition for prophylaxis or treatment of urinary system infection and method thereof |
| US20080114054A1 (en) * | 2006-11-14 | 2008-05-15 | Rath Microbes | Compositions and methods for reducing antimicrobial resistance of microbes |
-
2007
- 2007-05-28 MX MX2007006334A patent/MX2007006334A/es active IP Right Grant
-
2008
- 2008-05-27 PE PE2008000899A patent/PE20090316A1/es not_active Application Discontinuation
- 2008-05-27 CL CL2008001536A patent/CL2008001536A1/es unknown
- 2008-05-28 BR BRPI0811627-0A2A patent/BRPI0811627A2/pt not_active Application Discontinuation
- 2008-05-28 AR ARP080102250A patent/AR067320A1/es unknown
- 2008-05-28 EP EP08766681A patent/EP2149374B1/en not_active Not-in-force
- 2008-05-28 PL PL08766681T patent/PL2149374T3/pl unknown
- 2008-05-28 WO PCT/MX2008/000066 patent/WO2008147167A1/es active Application Filing
- 2008-05-28 ES ES08766681T patent/ES2394736T3/es active Active
-
2009
- 2009-11-12 GT GT200900295A patent/GT200900295A/es unknown
- 2009-11-13 CO CO09129713A patent/CO6241114A2/es not_active Application Discontinuation
- 2009-11-13 EC EC2009009733A patent/ECSP099733A/es unknown
-
2013
- 2013-01-10 CY CY20131100025T patent/CY1113544T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0811627A2 (pt) | 2014-11-11 |
| ES2394736T3 (es) | 2013-02-05 |
| CY1113544T1 (el) | 2016-06-22 |
| EP2149374B1 (en) | 2012-10-10 |
| PL2149374T3 (pl) | 2013-05-31 |
| WO2008147167A1 (es) | 2008-12-04 |
| AR067320A1 (es) | 2009-10-07 |
| MX2007006334A (es) | 2009-02-18 |
| ECSP099733A (es) | 2009-12-28 |
| EP2149374A4 (en) | 2010-12-08 |
| CL2008001536A1 (es) | 2009-04-03 |
| PE20090316A1 (es) | 2009-04-04 |
| CO6241114A2 (es) | 2011-01-20 |
| EP2149374A1 (en) | 2010-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6670567A2 (es) | Métodos de tratamiento contra el cáncer pancreático | |
| MD4577B1 (ro) | Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare | |
| CL2017002792A1 (es) | Derivados de ciclohexano sustituido con amido | |
| ECSP078023A (es) | Ingrediente farmacéutico activo en base a canabinoide | |
| DOP2006000057A (es) | Composición farmaceútica para el tratamiento del cáncer | |
| NZ708506A (en) | Methods of treating bladder cancer | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| CR11724A (es) | Agente para tratar enfermedades | |
| PE20142314A1 (es) | Composiciones intranasales de dexmedetomidina y metodos de uso de ellas | |
| CL2012002815A1 (es) | Composicion para el cuidado bucal que comprende uno o mas compuesto de curcumina y una fuente de iones de zinc; correspondiente a 0.02 a 3% en peso de citrato de zinc; y uso de una fuente de iones de zinc para suprimir la degradacion y/o decoloracion del compuesto de curcumina en una composicion ara el cuidado bucal. | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| ES2421731T3 (es) | Composición y procedimiento para el tratamiento de MRSA | |
| UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| MX2013003635A (es) | Compuestos de n-heteroarilo. | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| CO6400183A2 (es) | Formas de dosificación oral de bendamustina | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| AR091739A1 (es) | Composiciones y metodos para reducir el riesgo cardiometabolico | |
| CO6640318A2 (es) | Formas de dosificación oral de bendamustina | |
| GT200900235A (es) | Composiciones farmaceuticas | |
| GT200900296A (es) | Composición farmacéutica que comprende la combinación de un agente anti inflamatorio no esteroideo y un agente anticonvulsivante. | |
| GT200900295A (es) | Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias. | |
| PE20130308A1 (es) | Metodos para tratar infecciones bacterianas recurrentes | |
| CO6480929A2 (es) | Procedimiento de uso del factor liberador de corticotropina para el tratamiento del cancer |